![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Rabin Medical Center |
---|---|
Information provided by: | Rabin Medical Center |
ClinicalTrials.gov Identifier: | NCT00706212 |
PET CT is one of the imaging tools that are used for staging of urological malignancies.
C11 Choline is a novel isotope with the advantage of its minimal secretion in the urine. This advantage makes it a potentially better metabolic marker then others such as FDG. Preliminary studies showed ~95% sensitivity in the diagnosis of TCC. Our Goal is to continue the evaluation of this method as a diagnostic and follow up tool in different urological malignancies.
Condition |
---|
Urological Malignancies |
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Official Title: | A Comparative Study to Examine the Accuracy of CHOLINE PET CT in the Diagnosis |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Rabin Medical center Urological oncology patients
Inclusion Criteria:
Exclusion Criteria:
Contact: Shay Golan, MD | 972-50-744-7573 | shaygo1@yahoo.com |
Israel | |
Rabin Medical Center, Beilinson hospital | Recruiting |
Petach Tikva, Israel, 49100 | |
Principal Investigator: Shay Golan, MD |
Responsible Party: | Rabin Medical Center, Urology department ( Dr. Golan Shay ) |
Study ID Numbers: | GS-PET-2008 |
Study First Received: | June 26, 2008 |
Last Updated: | June 26, 2008 |
ClinicalTrials.gov Identifier: | NCT00706212 |
Health Authority: | Israel: Ethics Commission; Israel: Israeli Health Ministry Pharmaceutical Administration |
Choline |
Neoplasms |